title: Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans.
abstract: T-lymphocyte immunity is likely to be an important component of the immune defence against the AIDS virus, because helper T cells are necessary for the antibody response as well as the cytotoxic response. We have previously predicted two antigenic sites of the viral envelope protein gp120 likely to be recognized by T lymphocytes, based on their ability to fold as amphipathic helices, and have demonstrated that these are recognized by T cells of mice immunized with gp120 (ref. 1). A peptide corresponding to one of these sites can also be induce immunity in mice to the whole gp120 protein. Because many clinically healthy seropositive blood donors have already lost their T-cell proliferative response to specific antigen, we tested the response to these synthetic peptides of lymphocytes from 14 healthy human volunteers who had been immunized with a recombinant vaccinia virus containing the AIDS viral envelope gene and boosted with a recombinant fragment. Eight of the 14 responded to one peptide, and four to the other peptide, not included in the boost. These antigenic sites recognized by human T cells may be useful components of a vaccine against AIDS. We also found a correlation between boosting with antigen-antibody complexes (compared to free antigen) and higher stimulation indices, suggesting a more effective method of immunization.
authors: Metabolism Branch, National Cancer Institute, Bethesda, Maryland 20892.
authors: J A
authors: JA
authors: Berzofsky
authors: A
authors: A
authors: Bensussan
authors: K B
authors: KB
authors: Cease
authors: J F
authors: JF
authors: Bourge
authors: R
authors: R
authors: Cheynier
authors: Z
authors: Z
authors: Lurhuma
authors: J J
authors: JJ
authors: Salaün
authors: R C
authors: RC
authors: Gallo
authors: G M
authors: GM
authors: Shearer
authors: D
authors: D
authors: Zagury
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control; D000941:Antigens / Q000276:immunology*; D000939:Epitopes / Q000276:immunology; D006678:HIV / Q000276:immunology; D015699:HIV Envelope Protein gp120; D019302:HIV Envelope Protein gp160; D006680:HLA Antigens / Q000235:genetics / Q000276:immunology; D006801:Humans; D007114:Immunization; D007117:Immunization, Secondary; D010446:Peptide Fragments / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology; D012191:Retroviridae Proteins / Q000235:genetics / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology*; D014616:Vaccinia virus / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology*
chemical_list: D000941:Antigens; D000939:Epitopes; D015699:HIV Envelope Protein gp120; D019302:HIV Envelope Protein gp160; D006680:HLA Antigens; D010446:Peptide Fragments; D011994:Recombinant Proteins; D012191:Retroviridae Proteins; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins